57 results about "Genomic screening" patented technology

A method and apparatus are provided for identifying a biological sample obtained during either paternity screening, genetic screening, prenatal diagnosis, presymptomatic diagnosis, diagnosis to detect the presence of a target microorganism carrier detection analysis, forensic chemical analysis, or diagnosis of a subject to determine whether a subject is afflicted with a particular disease or disorder, or is at risk of developing a particular disorder, wherein the result obtained from the analysis is associated with the unique DNA fingerprint biological barcode of the genotype of the subject being analyzed. The methods and apparatus of the invention have application in the fields of diagnostic medicine, disease diagnosis in animals and plants, identification of genetically inherited diseases in humans, family relationship analysis, forensic analysis, and microbial typing.

Integrated systems, apparatus, software, and methods for performing biochemical analysis, including DNA sequencing, genomic screening, purification of nucleic acids and other biological components and drug screening are provided. Microfluidic devices, systems and methods for using these devices and systems for performing a wide variety of fluid operations are provided. The devices and systems of are used in performing fluid operations which require a large number of iterative, successive or parallel fluid manipulations, in a microscale, or sealed and readily automated format.

The invention relates to a pathogenic microorganism genome database and an establishment method thereof, and belongs to the technical field of meta-genomes. The method comprises the following steps ofdata acquisition, wherein pathogenic microorganism genome data is obtained; strain genome screening, wherein species strain genomes are selected according to a predetermined screening rule; plasmid sequence removal, wherein plasmid sequences existing in the strain genomes obtained in the last step are removed; filtration, wherein according to a predetermined filtering rule, strains with incorrectlabeling information, incomplete chromosome assembly and incorrect classification are removed to obtain a reference strain genome of the species; fusion genome construction, wherein the reference strain genome is interrupted, redundancy is removed, reassembly is performed, and the sequences are reassembled to obtain a fusion genome of the species; database assembly, wherein the above steps are repeated to obtain the fusion genome of the predetermined species, summary is performed, and the pathogenic microorganism genome database is obtained. The genome database has the advantages of not onlyhaving a high precision rate, but also having short analysis time and reducing the cost.

The invention discloses a deep-sea sediment-sourced novel esterase EST4 as well as an encoding gene and application thereof. A deep-sea sediment-sourced esterase gene est4 is obtained by screening a metagenome and has a nucleotide sequence shown as SEQ ID NO. 1, and the esterase EST4 encoded thereby has an amino acid sequence shown as SEQ ID NO. 2. After heterologous expression of the esterase gene provided by the invention, the catalytic activity is highest when a substrate is p-nitrophenol caproate (C6) and the enzymatic activity is 56.1U/mg. The optimum temperature for catalytic hydrolysis of the esterase EST4 is 35-40 DEG C; in the presence of Ca<2+>, Co<2+>, Sr<2+> and Zn<2+>, the enzymatic activity is increased. The esterase can be applied to chiral medicine synthesis, food processing and food flavor modification, wastewater treatment and washing industry and other industrial productions.

The invention discloses a recombinant escherichia coli capable of high-yielding L-methionine and an application thereof. The recombinant escherichia coli is constructed according to a method as follows: adopting a CRISPR-Cas9 gene editing technology for respectively replacing L-methionine synthase gene promoters with trc promoters in escherichia coli genomes, introducing a host strain genome and screening, thereby acquiring the recombinant escherichia coli capable of high-yielding L-methionine. The host strain is E.coli W3110 Delta metJ Delta metI/pTrc99A/metA*/yjeH which is constructed by knocking out metJ and metI in escherichia coli E.coli W3110 and then introducing a pTrc99A/metA*/yjeH plasmid. The maximal titer of L-methionine can reach up to 2.8g/L and DAP of by-products is obviouslyreduced to above 60% (reduced from 1g/L to below 0.4g/L).

The invention discloses a whole genome screening method for screening relative BPDE oncogenes and comprises the steps that: (1) genome DNA is extracted from normal lung tissue; (2) AFLP DNA fragment is prepared; (3) immunomagnetic of AFLP DNA fragment interacting with BPDE is enriched and separated; (4) AFLP PCR is increased; (5) denatured polyacrylamide gel electrophoresis and silver stain visualization are done to selective PCR amplification products of AFLP; (6) differential fragment is recycled, amplified, cloned and tested for sequence and homologous similarity and analysis are done. The whole genome screening method for screening relative BPDE oncogenes of the invention is the high effective and specific method and more BPDE susceptible oncogenes are screened in the whole genome level, which provides a basis for stating BPDE carcinogenic molecular mechanism.

The present invention provides methods and kits useful for genetic testing or screening of fetuses using nucleic acid samples isolated from cervical mucus samples of fetus hosts.

The invention discloses a method for developing an SSR (Simple Sequence Repeat) molecular mark of nibea albiflora for population identification. The method comprises the following steps: extracting RNA (Ribonucleic Acid) by using a nibea albiflora mixed tissue of a plurality of nibea albiflora, performing RNA sequencing, performing splicing to obtain a nibea albiflora expression gene sequence, and obtaining a potential SSR mark with a bioinformatics method; designing primers by utilizing an SSR flanking sequence, extracting genomic DNA (Deoxyribose Nucleic Acid) by using fins from a random sample, and screening the SSR primers; and performing PCR (Polymerase Chain Reaction) amplification on different nibea albiflora DNA templates by using each pair of the SSR primers, performing capillary electrophoresis detection on an amplification product by using a Qsep100 full-automatic nucleic acid analysis system, screening out primers with different amplification results, calculating allelic composition and allelic frequency by utilizing PopGene, and analyzing a nibea albiflora population relationship and a genetic structure. The SSR molecular mark method for identifying and verifying nibea albiflora groups, provided by the invention, is stable and reliable, is not influenced by ages, gender and growth seasons, and provides scientific bases for group analysis as well as species identification, breeding and evaluation of the nibea albiflora.

The invention relates to the technical field of genetic engineering and particularly discloses a recombinant yarrowia lipolytica bacterial strain as well as a construction method and an application thereof. A genome of the recombinant yarrowia lipolytica bacterial strain comprises a nucleotide sequence as shown in any one of SEQ ID NO: 1-3. The construction method comprises the following steps of constructing a key gene dhcr7 in a biosynthesis way of campesterol expressed by a single-gene expression cassette through an OE-PCR (overlap extension-polymerase chain reaction) method; cutting down the single-gene expression cassette through restriction enzyme, transferring the single-gene expression cassette into yeast at one time to perform homologous recombination among fragments and integration of a special erg5 lotus of the genome, screening a completely-assembled converter through an auxotrophic culture medium and genome PCR to obtain a novel recombinant yarrowia lipolytica bacterial strain. The novel recombinant yarrowia lipolytica bacterial strain can be applied to biosynthesis of campesterol, and a relatively high yield can be kept.

The present invention relates to modified vectors, e.g. plasmids, viruses or microbia sucsh as yeast or bacteria, wherein the replication, immunogenicity and/or pathogenicity is placed under the control of at least one stress gene regulating element. In preferred embodiments, these modified vectors are used for gene therapy, in vaccines, or for functional genomic screening.

Methods of introducing exogenous molecules into cells including cell lines and primary cells are provided. Additionally, miniaturized electroporation-ready microwell arrays are provided. These tools provide a miniaturized high-throughput functional genomics screening platform to carry out genome-size screens in a variety of cell types.

The present invention relates to the expression and screening of genomic DNA sequences encoding uncharacterized genes and proteins. The present invention provides systems utilizing unique features of retroviral replication to analyze uncharacterized genes derived from genomic DNA samples. In preferred embodiments, a segment of genomic DNA is inserted between 5′ and 3′ viral long terminal repeats (LTRs) in a vector (e.g., a plasmid, cosmid, or artificial chromosome vector). The resulting vector (or library of vectors containing a plurality of independent genomic sequences) is then introduced into a retroviral packaging cell. The resulting provirus or proteins expression from the provirus are then analyzed.

The invention provides a non-invasive technique for the differential detection of multiple genotypes and/or mutations for a plurality of target genes in a biological sample containing genetic material from different genomic sources. Methods are conducted using multiplex amplification of a plurality of target sequences from the biological sample, and sequencing is used to detect and enumerate genetic mutations and chromosomal abnormalities at the single nucleotide level.

The present invention relates to methods for treating a disease, in which the disease arises from dysregulation of the Wnt signaling pathway. In some instances, the disease can be treated by administering a Wnt pathway inhibitory compound. In other instances, the method optionally includes conducting a genome-wide screening to determine one or more genes resulting in a reduced disease state and then identifying the gene(s) as being involved in the Wnt signaling pathway.

The invention relates to genetic screens for susceptibility to Alzheimer's disease. In particular, the invention provides genetic screens based on genotyping of the p21E2c31 polymorphism and/or the p21E3+20 C/T polymorphism in the p21cip 1 gene.

The invention provides compositions and methods for performing mammalian cell genetics, e.g., genetic screens, using near-haploid cells. The invention further provides genes and gene products isolated using the inventive methods and methods of use thereof.

The present invention provides improved reverse hybrid assay methods for identifying amino acid residues within a protein that are required for its interaction or physical association with another protein, wherein disruption of an interaction between a protein of interest and its binding partner protein is assayed for a library of mutations of said protein of interest, and maintenance of an interaction between the protein of interest and another binding partner is assayed simultaneously in a single step, thereby reducing the incidence of uninformative mutations in the protein of interest that are detected.

A guide RNA comprising: a gRNA spacer sequence at the 5′ end of the guide RNA, wherein the spacer sequence is complementary to a target gene, a scaffold sequence that binds to Cas9, and an RNA capture and sequencing domain comprising: a barcode sequence, and a primer binding sequence; nucleic acids and vectors encoding the guide RNA; cells expressing the guide RNA; and a library comprising a plurality of guide RNAs. Also disclosed are methods of introducing a genetic perturbation into a cell, methods of assessing an effect of at least one genetic perturbation on RNA expression in a cell, methods of identifying nucleic acid sequences associated with a disease state and a method of identifying candidate therapeutic agents.